Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: SOP for Determination of Residual Solvents in Parenterals – V 2.0

Posted on By

Analytical Method Development: SOP for Determination of Residual Solvents in Parenterals – V 2.0

Standard Operating Procedure for Determination of Residual Solvents in Parenterals in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/279/2025
Supersedes SOP/AMD/279/2022
Page No. Page 1 of 12
Issue Date 21/05/2025
Effective Date 23/05/2025
Review Date 21/05/2026

1. Purpose

To establish a validated procedure for the identification and quantification of residual solvents in parenteral pharmaceutical products using Gas Chromatography (GC), ensuring compliance with

ICH Q3C guidelines and pharmacopeial standards (USP <467>).

2. Scope

This SOP applies to the Analytical Method Development and Quality Control departments responsible for monitoring residual solvent levels in parenteral dosage forms, including lyophilized powders, solutions, and emulsions during product development, validation, and routine testing.

3. Responsibilities

  • Analytical Chemist: Develops, validates, and executes the GC method for residual solvents.
  • QC Analyst: Conducts batch testing using the validated method.
  • QA Executive: Reviews test data, validation reports, and ensures compliance with regulatory standards.
See also  Analytical Method Development: Derivatization Techniques in GC - V 2.0

4. Accountability

The Head of Analytical Method Development is accountable for implementing and maintaining validated procedures to monitor and control residual solvents in compliance with regulatory guidelines.

5. Procedure

5.1 Target Solvents

Include solvents classified under ICH Q3C as Class 1, 2, and 3 (e.g., methanol, acetone, ethanol, dichloromethane, toluene, acetonitrile, benzene).

5.2 Sample Preparation

  1. Weigh 0.5 to 1.0 g of the sample into a headspace vial.
  2. Add 5 mL of dimethyl sulfoxide (DMSO) or water as diluent.
  3. Seal vial with PTFE-lined septa under inert atmosphere (e.g., nitrogen).

5.3 Standard Preparation

  1. Prepare stock solutions of each residual solvent in DMSO.
  2. Prepare working standards containing known concentrations of target solvents for calibration curve generation.
  3. Include internal standard (e.g., 1-propanol or butanol) if required by the method.

5.4 GC Conditions (Typical)

  • Column: Fused silica capillary column (e.g., DB-624, 30 m × 0.32 mm, 1.8 µm film thickness)
  • Carrier Gas: Helium at 1.5 mL/min
  • Injector: Headspace sampler or direct injection, split/splitless mode
  • Detector: Flame Ionization Detector (FID)
  • Oven Program: Initial temp 40°C (hold 10 min), ramp to 220°C at 10°C/min
See also  Analytical Method Development: SOP for Cleaning of Sample Preparation Area - V 2.0

5.5 Validation Parameters

  1. Specificity: No interference at retention times of analytes and internal standard.
  2. Linearity: r² ≥ 0.995 over a range of 50%–150% of specification limit.
  3. Accuracy: Recovery between 95%–105% at three concentration levels.
  4. Precision: %RSD ≤ 5.0% for replicate injections.
  5. LOD/LOQ: Based on signal-to-noise ratio of 3:1 and 10:1, respectively.
  6. Robustness: Evaluate stability of results with variations in flow rate, oven temp, and injection volume.

5.6 Acceptance Criteria (ICH Q3C)

  • Class 1: Must not be present above detection limit (e.g., benzene < 2 ppm)
  • Class 2: Within specified limits (e.g., methanol ≤ 3000 ppm)
  • Class 3: Not more than 5000 ppm unless otherwise justified

6. Abbreviations

  • GC: Gas Chromatography
  • DMSO: Dimethyl Sulfoxide
  • FID: Flame Ionization Detector
  • RSD: Relative Standard Deviation
  • ICH: International Council for Harmonisation

7. Documents

  1. Residual Solvent Test Log – Annexure-1
  2. GC Calibration Report – Annexure-2
  3. Method Validation Summary – Annexure-3

8. References

  • USP <467>: Residual Solvents
  • ICH Q3C(R6): Impurities – Guideline for Residual Solvents
  • Ph. Eur. 2.4.24: Identification and Control of Residual Solvents

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name Ritu Choudhary Ankit Mehra Sunita Reddy
Designation GC Analyst QA Reviewer Head – AMD
Department Analytical Method Development QA Analytical Method Development

11. Annexures

Annexure-1: Residual Solvent Test Log

Sample ID Solvent Detected (ppm) Limit (ppm) Status
RS-279-01 Methanol 2500 3000 Pass

Annexure-2: GC Calibration Report

Linearity established for methanol, ethanol, acetone, and dichloromethane over 50%–150% range with r² ≥ 0.998. Retention time reproducible within ±0.1 min.

Annexure-3: Method Validation Summary

The method was successfully validated for detection of residual solvents in lyophilized and solution-based parenteral formulations. Compliant with USP <467> and ICH Q3C. Suitable for routine QC and regulatory submission.

Revision History:

Revision Date Revision No. Details Reason Approved By
21/05/2025 2.0 Updated GC conditions and validation parameters Annual Review Sunita Reddy
05/05/2022 1.0 Initial SOP Release New SOP QA Head
See also  Analytical Method Development: Qualification of Method Development Instruments - V 2.0
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Reviewing SOP Execution Logs Before Regulatory Audits
Next Post: Elixir Department: SOP for Homogeneity Sampling – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version